Mig Junior (Ibuprofen)

Ibuprofen works by blocking the cyclooxygenase‑1 and cyclooxygenase‑2 (COX‑1 and COX‑2) enzymes. This inhibition reduces the production of prostaglandins, which are chemicals that promote pain, fever, and inflammation, thereby providing analgesic, antipyretic, and anti‑inflammatory effects.

The appropriate dose of Mig Junior is determined by a qualified prescriber based on the child’s age, weight, and clinical condition. Healthcare professionals follow established dosing guidelines for pediatric ibuprofen and adjust the amount as needed for safety and effectiveness.

Safety of ibuprofen in pregnancy and breastfeeding has not been definitively established. Women who are pregnant, planning to become pregnant, or nursing should discuss the use of Mig Junior with their healthcare provider to weigh potential risks and benefits.

To place an order, submit an enquiry on the Mig Junior product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mig Junior’s ibuprofen is an NSAID, offering both analgesic and anti‑inflammatory actions, unlike acetaminophen which provides pain relief and fever reduction without significant anti‑inflammatory effects. Compared with aspirin, ibuprofen generally has a lower risk of gastrointestinal irritation and is preferred for pediatric use.

Mig Junior should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mig Junior is taken orally. The dosage form is designed for easy swallowing or, if supplied as a liquid, can be measured with a calibrated dosing device. It should be taken with or without food, as directed by the prescriber.

Serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis, renal impairment, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms such as vomiting blood, severe stomach pain, rash, or difficulty breathing.

Mig Junior should be avoided by individuals with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, patients with severe renal or hepatic impairment, and children under the age for which the product is formulated unless specifically prescribed.